Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | ACACA | Q13085 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23338585 | 0.80 | HRH3 (0.32) | — | |
| SCHEMBL25895238 | 0.78 | AOC2 (0.34) | — | |
| SCHEMBL25793718 | 0.78 | NEK2 (0.40) | CHRM2CHRM3ACACBACACA | |
| SCHEMBL22156305 | 0.78 | CHRM2 (0.36) | CHRM2CHRM3ACACBACACA | |
| SCHEMBL25919795 | 0.76 | — | — | |
| SCHEMBL22313302 | 0.74 | CHRM2 (0.43) | CHRM2CHRM3ACACBACACA | |
| SCHEMBL20420098 | 0.73 | ACACB (0.35) | CHRM2CHRM3ACACBACACA | |
| SCHEMBL9963249 | 0.72 | CHRM2 (0.37) | CHRM2CHRM3ACACBACACA | |
| SCHEMBL23342180 | 0.71 | AOC2 (0.33) | ACACBACACA | |
| SCHEMBL22036423 | 0.70 | CHRM2 (0.56) | CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20210130326-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739074-B2 | Ras inhibitors | KRAS, NRAS, HRAS | CHRM2 4885/4885CHRM3 4879/4885ACACB 3313/4885 |
| US-20210130326-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CHRM2 4885/4885CHRM3 4874/4885ACACB 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.